Abstract | OBJECTIVE: METHODS: RESULTS: From January 1, 2011, to November 30, 2013, we identified 62 mother-neonate dyads, 31 treated with methadone and 31 treated with buprenorphine and naloxone. Sixteen neonates (51.6%) in the methadone group were diagnosed with neonatal abstinence syndrome compared with eight (25.1%) in the buprenorphine and naloxone group (adjusted odds ratio 2.55, 95% confidence interval [CI] 1.31-4.98, P = .01). The buprenorphine and naloxone-exposed neonates had lower peak neonatal abstinence syndrome scores (9.0 ± 4.4 compared with 10.7 ± 3.7, multivariate-adjusted mean difference = -2.77, 95% CI -4.99 to -0.56, P = .02) and shorter overall hospitalization (5.6 ± 5.0 compared with 9.8 ± 7.4 days, multivariate-adjusted mean difference = -3.90, 95% CI, -7.13 to -0.67, P = .02). We found no other differences in primary or secondary outcomes. CONCLUSION:
|
Authors | Samantha L Wiegand, Elizabeth M Stringer, Alison M Stuebe, Hendree Jones, Carl Seashore, John Thorp |
Journal | Obstetrics and gynecology
(Obstet Gynecol)
Vol. 125
Issue 2
Pg. 363-368
(Feb 2015)
ISSN: 1873-233X [Electronic] United States |
PMID | 25569005
(Publication Type: Comparative Study, Journal Article, Research Support, N.I.H., Extramural)
|
Chemical References |
- Narcotic Antagonists
- Narcotics
- Naloxone
- Buprenorphine
- Methadone
|
Topics |
- Adult
- Buprenorphine
(adverse effects)
- Female
- Humans
- Infant, Newborn
- Methadone
(adverse effects)
- Naloxone
(adverse effects)
- Narcotic Antagonists
(adverse effects)
- Narcotics
(adverse effects)
- Neonatal Abstinence Syndrome
(prevention & control)
- Opiate Substitution Treatment
(adverse effects)
- Opioid-Related Disorders
(drug therapy)
- Pregnancy
- Pregnancy Complications
(drug therapy)
- Retrospective Studies
- Young Adult
|